Business Milestones
2025.06.13
TAHO Pharmaceuticals to Showcase Cardiovascular Innovations at BIO International Convention 2025
Taipei — June 13, 2025
TAHO Pharmaceuticals announced that it is invited to present at BIO International Convention 2025, the world’s premier biotechnology event, held in Boston, MA, from June 16-19, 2025. The company will deliver a presentation on Wednesday, June 18, 2025, at 9:45 AM in Room 153C at the Boston Convention and Exhibition Center.
The presentation will highlight the successful data from the pivotal trial of TAH3311, an oral dissolving film (ODF) formulation of apixaban, designed to reduce stroke and systemic embolism risks with enhanced patient convenience. This presentation will underscore TAHO’s innovative cardiovascular portfolio and its proprietary Transepithelial Delivery System (TDS), which enables advanced transdermal and transmucosal drug delivery for niche markets. Additionally, company representatives will be available for one-on-one meetings throughout the conference to discuss potential partnerships and collaborations.
The BIO International Convention, hosted by the Biotechnology Innovation Organization (BIO), is expected to attract over 20,000 industry leaders from the biotech, pharmaceutical, and financial sectors, facilitating more than 61,000 partnering meetings. To schedule a meeting, contact TAHO at ir@tahopharma.com or use the BIO Partnering system.
About TAHO Pharmaceuticals Ltd.
Founded in 2010, TAHO Pharmaceuticals Ltd. leverages its proprietary Transepithelial Delivery System (TDS) to overcome the limitations of existing drugs and develop innovative dosage forms for niche markets. The TDS platform combines advanced transdermal and transmucosal delivery technologies, enabling the development of unique dosage forms such as transdermal patches, ODF, and buccal films. TAHO’s diverse product portfolio spans a variety of therapeutic areas, including antithrombotic agents, opioid overdose antidotes, addiction treatments, pediatric ADHD, and chemotherapy-induced antiemetics. Among its notable achievements, TAH4411, an ODF for chemotherapy-induced nausea and vomiting, became the first product of its kind to receive regulatory approval and be commercialized in Japan.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
ir@tahopharma.com
TAHO Pharmaceuticals announced that it is invited to present at BIO International Convention 2025, the world’s premier biotechnology event, held in Boston, MA, from June 16-19, 2025. The company will deliver a presentation on Wednesday, June 18, 2025, at 9:45 AM in Room 153C at the Boston Convention and Exhibition Center.
The presentation will highlight the successful data from the pivotal trial of TAH3311, an oral dissolving film (ODF) formulation of apixaban, designed to reduce stroke and systemic embolism risks with enhanced patient convenience. This presentation will underscore TAHO’s innovative cardiovascular portfolio and its proprietary Transepithelial Delivery System (TDS), which enables advanced transdermal and transmucosal drug delivery for niche markets. Additionally, company representatives will be available for one-on-one meetings throughout the conference to discuss potential partnerships and collaborations.
The BIO International Convention, hosted by the Biotechnology Innovation Organization (BIO), is expected to attract over 20,000 industry leaders from the biotech, pharmaceutical, and financial sectors, facilitating more than 61,000 partnering meetings. To schedule a meeting, contact TAHO at ir@tahopharma.com or use the BIO Partnering system.
About TAHO Pharmaceuticals Ltd.
Founded in 2010, TAHO Pharmaceuticals Ltd. leverages its proprietary Transepithelial Delivery System (TDS) to overcome the limitations of existing drugs and develop innovative dosage forms for niche markets. The TDS platform combines advanced transdermal and transmucosal delivery technologies, enabling the development of unique dosage forms such as transdermal patches, ODF, and buccal films. TAHO’s diverse product portfolio spans a variety of therapeutic areas, including antithrombotic agents, opioid overdose antidotes, addiction treatments, pediatric ADHD, and chemotherapy-induced antiemetics. Among its notable achievements, TAH4411, an ODF for chemotherapy-induced nausea and vomiting, became the first product of its kind to receive regulatory approval and be commercialized in Japan.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
ir@tahopharma.com